|Bid||0.00 x 2200|
|Ask||0.00 x 800|
|Day's Range||35.58 - 38.22|
|52 Week Range||16.50 - 38.22|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||40.78|
Over the past few years, Cathie Wood's ARK Invest group of exchange-traded funds have delivered impressive gains. ARK Invest's most successful fund over the past year, the ARK Genomic Revolution ETF (NYSEMKT: ARKG) has the best performer of the bunch with an incredible 80% gain over the past 12 months. On Jun. 3, 2021, the ARK Genomic Revolution ETF bought shares of these two clinical-stage biotechs.
Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference.
We have been pretty impressed with the performance at Dicerna Pharmaceuticals, Inc. ( NASDAQ:DRNA ) recently and CEO...